{"schema":"sb.node.v1","id":"sb:e/67d79df678500718ed56cfe3","kind":"entity","label":{"text":"ctla-4","locale":"en"},"identity":{"anchor":"label:en:ctla-4","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T15:58:04.276991+00:00","snapshot":"deploy 7e1a8471a23e0f1eb0285c67fee8a6f7d073739a"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":30,"separatePublishers":14,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-29","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.233: about 77% of mentions carry no typed assertion"]}},"dimensions":{"domains":["precision_medicine","auto"],"activeDays":21,"assertions":{"military-action":3,"funding-round":2,"regulatory-approval":1,"election":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/da75caf77e736e7344c7f26b","kind":"observation","label":"Fierce Biotech · 2026-09-09 · Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2","url":"https://www.fiercebiotech.com/biotech/solstice-rises-225m-advance-second-gen-ctla-4-immunotherapy"},{"id":"sb:o/1ae3cf924bd8d008ae94c8ac","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-07 · Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1936605"},{"id":"sb:o/fd2b90ebec605b1bc55dbd54","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-06 · Coya Therapeutics Completes Enrollment of 120 Patients in COYA 302 ALS Trial","url":"https://www.clinicaltrialvanguard.com/news/coya-therapeutics-completes-enrollment-of-120-patients-in-coya-302-als-trial/"},{"id":"sb:o/0477f33f1f92913ab49329a4","kind":"observation","label":"Financial Post · 2026-10-04 · Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026","url":"https://financialpost.com/pmn/business-wire-news-releases-pmn/agenus-reports-48-estimated-three-year-survival-with-botbal-in-recurrent-ovarian-cancer-at-igcs-2026"},{"id":"sb:o/87972f89a9ad612147f5e4f1","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-02 · Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1967814"},{"id":"sb:o/ffc5ab21f3cd98dbaaa4f8e4","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-01 · Molecular profiling and prognostic significance of gastric cancer subtypes based on extracellular vesicle-related characteristics","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1948199"},{"id":"sb:o/5139276ccdf255cc76f61bb2","kind":"observation","label":"AllSci News · 2026-09-30 · Vividion’s WRN inhibitor shows first clinical proof of synthetic lethality in MSI-high cancers","url":"https://allsci.com/news/biotech/vvd-214-colorectal-cancer-msi-high-achieves/"},{"id":"sb:o/e1bdb524d2b54df0d27d087c","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-30 · Editorial: Novel theragnostic approaches in thoracic malignancies","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.2006660"},{"id":"sb:o/edbdbef0e42c95af29a482f4","kind":"observation","label":"bioRxiv Cancer Biology · 2026-09-29 · Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma","url":"https://www.biorxiv.org/content/10.64898/2026.09.28.754895v1?rss=1"},{"id":"sb:o/f61c9c9d1612b3dd79ad3e21","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-29 · Case Report: Immune checkpoint inhibitor–induced hypophysitis presenting as acute paralytic ileus mimicking mechanical bowel obstruction in a patient affec…","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1934901"}],"cursor":"c1.eyJpZCI6InNiOmUvNjdkNzlkZjY3ODUwMDcxOGVkNTZjZmUzIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDE1OjU4OjA0LjI3Njk5MSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with immunotherapy (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/51f6af249a8a0878db6c09c6"},{"kind":"relation","label":"co-mentioned with ai (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/29b93510c1f680b986523c90"},{"kind":"relation","label":"co-mentioned with disclaimer (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d39edc2261079964df3b48db"},{"kind":"relation","label":"co-mentioned with creative commons (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3e3f1a1d1f3a751bd0d66c95"},{"kind":"relation","label":"co-mentioned with solid tumors (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/da1eefe72658888aecd7ab92"},{"kind":"relation","label":"co-mentioned with china (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/bc7a7b14adeb42c81052d082"},{"kind":"relation","label":"co-mentioned with size (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1b4cedcd5310a03d10a2df93"},{"kind":"relation","label":"co-mentioned with t-cell (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/14f6d942f49eefd204cafc95"},{"kind":"relation","label":"co-mentioned with clinical trial (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/480c890a48127d0898874913"},{"kind":"relation","label":"co-mentioned with fda (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/bf9a5e9084c30ad28f5dc2f1"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/67d79df678500718ed56cfe3","mcp":"traverse {\"id\":\"sb:e/67d79df678500718ed56cfe3\"}","page":"/entity/ctla-4/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/67d79df678500718ed56cfe3\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/67d79df678500718ed56cfe3\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/67d79df678500718ed56cfe3\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/67d79df678500718ed56cfe3\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}